Caricamento...
Targeting the programmed cell death 1 pathway in Hodgkin lymphoma: the place of nivolumab
Nivolumab is a humanized immunoglobulin gamma-4 kappa anti-programmed cell death 1 monoclonal antibody that is currently approved in the treatment of several solid tumors and recently gained accelerated approval in classical Hodgkin lymphoma (cHL) that has relapsed or progressed following autologous...
Salvato in:
| Pubblicato in: | Ther Adv Hematol |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
SAGE Publications
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5407507/ https://ncbi.nlm.nih.gov/pubmed/28473905 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620717695723 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|